Powered by

Cybrexa Therapeutics Selects Lead Clinical Candidate CBX-11, Combining its alphalex„¢ Technology with an Approved PARP Inhibitor to Treat Various Solid Tumors in Combination with Chemotherapy

Jan 02, 2019 - GlobeNewswire

CBX-11 selected based on robust efficacy and safety in combination with chemotherapy demonstrated in preclinical models

Positive pre-IND Meeting with FDA supports on track plan to file IND in Q4 2019

NEW HAVEN, Conn., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex„¢ tumor-targeting platform, today announced that it has selected CBX-11 as its lead clinical development candidate for...